SURGE: Supporting UnderRepresented Minorities in Genomics-based Cancer Trial Enrollment (Intervention)
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorNadine McCleary, MD, MPH
About this trial
SURGE aims to increase equity in clinical trial enrollment by addressing barriers to genomic testing, which is increasingly needed to assess precision clinical trial eligibility and access standard precision therapies. The study is an interventional pilot meant primarily to assess the feasibility of the intervention. The intervention is comprised of a patient navigator, text message questionnaire, and informational video.
Eligibility criteria
Qualifiers
Adult (age 18 years or older)
Black, Latinx, OR older adult (age 70 years or older)
Scheduled for a new patient consultation
Suspected or confirmed advanced malignancy (requiring active treatment)
Disqualifiers
Malignancy or former malignancy that requires only surveillance
Not continuing care at a participating DFCI site
Speaks a language other than English or Spanish
Unable to provide consent
Trial design
Treatments tested in this trial
- SURGE
Treatment groups
210 Participants
are divided into 3 treatment groupsSponsors and collaborators
Nadine McCleary, MD, MPH
Lead sponsor
Dana-Farber Cancer Institute
Sponsor institution
Bristol-Myers Squibb
Collaborator
Source ClinicalTrials.gov